Analysts Set Context Therapeutics Inc. (NASDAQ:CNTX) Target Price at $6.60

Context Therapeutics Inc. (NASDAQ:CNTX) has received a consensus recommendation of “Moderate Buy” from the eight ratings firms that are covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, six have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month price objective among brokerages that have issued a report on the stock in the last year is $6.60.

Several research analysts have recently commented on CNTX shares. Lifesci Capital raised Context Therapeutics to a “strong-buy” rating in a research report on Monday, February 23rd. D. Boral Capital reaffirmed a “buy” rating and set a $9.00 target price on shares of Context Therapeutics in a research report on Tuesday, March 24th. Piper Sandler upped their target price on Context Therapeutics from $4.00 to $7.00 and gave the company an “overweight” rating in a research report on Tuesday, March 24th. Wall Street Zen raised Context Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, May 9th. Finally, Guggenheim reaffirmed a “buy” rating and set a $5.00 target price on shares of Context Therapeutics in a research report on Tuesday, March 24th.

Context Therapeutics Trading Up 8.3%

CNTX opened at $2.60 on Friday. The firm has a market cap of $238.89 million, a price-to-earnings ratio of -6.19 and a beta of 1.57. Context Therapeutics has a 12 month low of $0.49 and a 12 month high of $3.62. The stock has a fifty day moving average price of $2.55 and a 200-day moving average price of $1.98.

Context Therapeutics (NASDAQ:CNTX) last released its quarterly earnings results on Wednesday, May 6th. The company reported ($0.09) EPS for the quarter, topping the consensus estimate of ($0.12) by $0.03. On average, equities research analysts forecast that Context Therapeutics will post -0.35 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. Virtu Financial LLC acquired a new position in Context Therapeutics during the 4th quarter valued at about $43,000. Sanctuary Advisors LLC acquired a new position in Context Therapeutics during the 1st quarter valued at about $51,000. Quadrature Capital Ltd acquired a new position in Context Therapeutics during the 4th quarter valued at about $68,000. Citadel Advisors LLC acquired a new position in Context Therapeutics during the 3rd quarter valued at about $100,000. Finally, XTX Topco Ltd increased its position in Context Therapeutics by 858.8% during the 4th quarter. XTX Topco Ltd now owns 101,605 shares of the company’s stock valued at $149,000 after buying an additional 91,008 shares in the last quarter. 14.03% of the stock is owned by institutional investors and hedge funds.

Context Therapeutics Company Profile

Context Therapeutics (NASDAQ: CNTX) is a clinical-stage biopharmaceutical company focused on the discovery and development of precision therapies for genetically defined patient populations in oncology. The company’s research model centers on identifying novel targets and designing small-molecule and biologic candidates that address key drivers of tumor growth and resistance. Context Therapeutics leverages a biomarker-driven approach to maximize the probability of clinical response, tailoring its development programs to specific molecular subgroups within solid tumors.

With a pipeline advancing through early clinical trials, Context Therapeutics emphasizes strategic collaborations and academic partnerships to accelerate the translation of laboratory findings into patient-focused studies.